- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01324193
Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in CKD Patients
Effects of Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in Chronic Kidney Disease Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic kidney disease (CKD) patients have very low physical function and high rates of cardiovascular disease (CVD) mortality. The objective of the proposed research is to evaluate the effects of dietary supplementation with a pomegranate extract, that contains high amounts of antioxidants, on physical function and CVD risk. Patients with moderate to severe chronic kidney disease that are NOT yet on dialysis tend to have significantly reduced risk factors for cardiovascular disease (and other disorders) compared to dialysis patients. This includes significantly reduced systemic markers of oxidative stress and inflammation. As a result, therapies designed to reduce the risk of CKD co-morbidities may differ significantly in dialysis and pre-dialysis patients. For example, dialysis patients are recommended to INCREASE their intake of dietary protein, while pre-dialysis patients are recommended to DECREASE their protein intake, due to differences in the pathophysiology of the two conditions. The investigators have decided to recruit pre-dialysis patients in addition to dialysis patients in this study because the investigators believe this will help us determine if the efficacy of pomegranate differs between patients with different stages of CKD.
CKD patients will be recruited under 2 phases: CKD patients not receiving dialysis treatment (pre-dialysis patients) will be recruited in the first phase. This will include patients with CKD stage 3-5 that are not yet on dialysis. In the second phase, only CKD patients on dialysis treatment will be recruited. To address these questions, CKD patients will be randomized to the following groups for 12 months: 1) no POM supplementation/control (CON), and 2) oral supplementation with purified pomegranate extract (POM). Patients in the POM group will ingest a 1000 milligram capsule of POM extract, 7 days per week. Patients in the CON group will receive a placebo capsule using the same protocol.
On three occasions, at baseline, 6, and 12 months, each subject will have blood collected to measure plasma markers of oxidative stress (TBARS, lipid peroxides), blood lipid levels, and glucose and insulin levels. Arterial and cardiac structure and function will be measured by vascular ultrasound and echocardiogram, respectively. A 24-hour dietary recall will be used to assess the intake of nutrients. Leg strength will be measured on a resistance exercise machine. Bone density and body composition will be evaluated using dual energy x-ray absorptiometry (DXA). Pre-dialysis subjects will undergo a maximal exercise test to assess their cardiorespiratory fitness level. In dialysis patients, instead of a maximal exercise test, physical function will be measured by a 6-item functional fitness assessment and a 10-meter walk test.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Champaign, Illinois, United States, 61820
- Champaign-Urbana Dialysis Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1) Subjects must be diagnosed with CKD stage 3, 4 or 5 (glomerular filter rate < 59 mL/min).
- 2) Subjects must be ≥ 30 years of age, to increase the probability of having developed significant arterial stiffness.
- 3) Subjects must be willing to be randomized to the control or intervention groups. The health history questionnaire and PAR-Q will be used to determined eligibility.
Subjects must complete a medical history and a nephrologist must sign off on a medical clearance for the subject before they can begin the study.
Exclusion Criteria:
- 1) Subjects < 30 years of age.
- 2) Subjects who are not willing to be randomized to one of the two groups.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Pre-diaylsis patients
Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
|
a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc.
Los Angeles, CA)7 days a week for 12 months.
|
Other: Dialysis patients
Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
|
a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc.
Los Angeles, CA)7 days a week for 12 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Markers of oxidative stress
Time Frame: Circulating markers of oxidative stress will be reduced and serum antioxidant activity will be increased in POM, compared to CON after 12 months of intervention.
|
Circulating markers of oxidative stress will be reduced and serum antioxidant activity will be increased in POM, compared to CON after 12 months of intervention.
|
Markers of inflammation
Time Frame: Circulating markers of inflammation will be reduced in POM, compared to CON after 12 months of intervention.
|
Circulating markers of inflammation will be reduced in POM, compared to CON after 12 months of intervention.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cardiovascular risk
Time Frame: Carotid artery stiffness and CIMT will be reduced in POM compared to CON after 12 months.
|
Carotid artery stiffness and CIMT will be reduced in POM compared to CON after 12 months.
|
Muscular performance
Time Frame: Muscle strength and physical performance will be reduced in CON compared to POM after 12 months
|
Muscle strength and physical performance will be reduced in CON compared to POM after 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth Wilund, PhD, University of Illinois at Chicago
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10041 (Registry Identifier: DAIDS ES)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
-
Penn State UniversityAlmond Board of California; The Hershey CompanyCompletedCardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentCompleted
-
Aziyo Biologics, Inc.CompletedCardiovascular DiseaseUnited States
-
Monash UniversityCompletedCardiovascular DiseaseAustralia
Clinical Trials on Pomegranate extracts
-
Cairo UniversityCompleted
-
National Research Council, SpainHospital Universitario Reina Sofia de CordobaCompletedColorectal CancerSpain
-
Fundación Pública Andaluza para la gestión de la...RecruitingStroke | Ischemic Stroke | Brain Ischemia | Neurovascular InjurySpain
-
Hillel Yaffe Medical CenterUnknown
-
Dalin Tzu Chi General HospitalCompletedHearing ImpairmentTaiwan
-
University of California, Los AngelesCompletedSkin Photoaging, Inflammation and Skin Pathogenic BacteriaUnited States
-
University of ZurichTerminated
-
University of California, Los AngelesCompletedCardiovascular Diseases
-
Roll International CorporationUnknownProstate CancerUnited States
-
Jonsson Comprehensive Cancer CenterCompletedProstate CancerUnited States